Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$75.14M |
$0.89
+3.53%
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$74.98M |
$0.78
+2.01%
|
|
GUTS
Fractyl Health, Inc. Common Stock
Revita DMR System is a medical device used in outpatient endoscopic/metabolic procedures, representing a direct product Fractyl Health develops and sells.
|
$74.43M |
$1.49
+1.71%
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$74.24M |
$2.35
+1.08%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$73.90M |
$1.39
-4.48%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$72.98M |
$3.73
+10.50%
|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$72.30M |
$1.03
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$71.59M |
$1.32
-0.38%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$71.12M |
$1.45
-4.61%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$71.01M |
$1.34
+0.37%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$70.07M |
$1.19
+0.42%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$69.59M |
$0.72
+1.16%
|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$69.51M |
$2.29
-2.34%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$69.15M |
$0.70
-0.68%
|
|
SIGY
Sigyn Therapeutics, Inc.
Sigyn Therapy is a broad-spectrum blood purification device designed to remove pathogens, toxins, and inflammatory mediators from blood.
|
$68.37M |
$1.40
|
|
SRTS
Sensus Healthcare, Inc.
Sensus manufactures medical devices and biometric sensing technologies, including SRT therapy systems and related imaging components.
|
$67.57M |
$4.13
-2.93%
|
|
VATE
INNOVATE Corp.
MediBeacon and R2 Technologies manufacture medical devices/biometrics (skin therapy devices and transdermal kidney function monitoring).
|
$67.35M |
$5.14
|
|
LUNG
Pulmonx Corporation
Zephyr Endobronchial Valve and related medical devices are core product offerings.
|
$66.42M |
$1.65
-2.94%
|
|
AMWL
American Well Corporation
Amwell uses Carepoint and related hardware as part of its care-delivery ecosystem, aligning with medical devices/biometrics.
|
$66.39M |
$4.11
+1.48%
|
|
AKYA
Akoya Biosciences, Inc.
Engagement in companion diagnostics through clinical collaborations (e.g., Acrivon, NeraCare).
|
$64.26M |
$1.29
|
|
TISI
Team, Inc.
Laboratory Testing & Advisory Services aligns with Team's lab testing and inspection capabilities within its IHT segment.
|
$63.88M |
$14.52
+0.10%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$63.67M |
$1.06
+3.40%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$63.43M |
$1.70
+1.80%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$63.38M |
$6.76
+32.03%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$63.07M |
N/A
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$62.99M |
$1.10
+12.93%
|
|
NNBR
NN, Inc.
Precision medical device components manufacturing, including implant-related parts (Medical Device Components).
|
$62.87M |
$1.25
-7.38%
|
|
ABVC
ABVC BioPharma, Inc.
ABV-2002 is a corneal storage solution, placing ABVC in ophthalmic drug products.
|
$62.86M |
$2.68
+4.28%
|
Showing page 27 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
